Changing Trends in Pacemaker and Implantable Cardioverter Defibrillator Generator Advisories

MAISEL, W.H., et al.: Changing Trends in Pacemaker and Implantable Cardioverter Defibrillator Generator Advisories. Pacemaker and implantable cardioverter defibrillator (ICD) generator recalls and safety alerts (advisories) occur frequently, affect many patients, and are increasing in number and rate. It is unknown if advances in device technology have been accompanied by changing patterns of device advisory type. Weekly FDA Enforcement Reports from January 1991 to December 2000 were analyzed to identify all advisories involving pacemaker and ICD generators. This article represents additional analysis of previously cited advisories and does not contain additional recalls or safety alerts over those that have been previously reported. The 29 advisories (affecting 159,061 devices) from the early 1990s (1991–1995) were compared to the 23 advisories (affecting 364,084 devices) from the late 1990s (1996–2000). While the annual number of device advisories did not change significantly, ICD advisories became more frequent and a three‐fold increase in the number of devices affected per advisory was observed. The number of devices affected by hardware advisories increased three‐fold, due primarily to a 700‐fold increase in electrical/circuitry abnormalities and a 20‐fold increase in potential battery/capacitor malfunctions. Other types of hardware abnormalities (defects in the device header, hermetic seal, etc.) became less common. The number of devices recalled due to firmware (computer programming) abnormalities more than doubled. The remarkable technological advances in pacemaker and ICD therapy have been accompanied by changing patterns of device advisory type. Accurate, timely physician and patient notification systems, and routine pacemaker and ICD patient follow‐up continue to be of paramount importance.

[1]  G. Tyers FDA recalls: how do pacemaker manufacturers compare? , 1989, The Annals of thoracic surgery.

[2]  Victor Parsonnet,et al.  The Bilitch Report: Performance of Implantable Cardiac Rhythm Management Devices , 1989 .

[3]  The Impact of a Manufacturer's Revision of Pacemaker Service Life on the Workload of a Large Pacing Center , 1989, Pacing and clinical electrophysiology : PACE.

[4]  D. Hayes,et al.  Report of the Policy Conference of NASPE on Device/Lead Performance and the Development of a Postmarket Surveillance Database , 1993, Journal of interventional cardiology.

[5]  D. Hayes,et al.  Report of the Policy Conference of NASPE on device/lead performance and the development of a postmarket surveillance database. The Writing Committee. , 1993, Pacing and clinical electrophysiology : PACE.

[6]  N. Finch,et al.  The impact of device recall on patients and family members of patients with automatic implantable cardioverter defibrillators. , 1994, Heart & lung : the journal of critical care.

[7]  D. Newman,et al.  Management of Intracardiac Device Recalls: A Consensus Conference , 1996, The Canadian journal of cardiology.

[8]  S. Furman,et al.  Failure Rates of Leads, Pulse Generators, and Programmers Have Not Diminished Over the Last 20 Years: Formal Monitoring of Performance is Still Needed , 1996, Pacing and clinical electrophysiology : PACE.

[9]  The Potential World Market for Cardiovascular and Medical Devices. , 1997, The Journal of invasive cardiology.

[10]  Runaway Pacemaker in an Implantable Cardioverter Defibrillator , 1998, Journal of cardiovascular electrophysiology.

[11]  J. Brinker,et al.  Risks of spontaneous injury and extraction of an active fixation pacemaker lead: report of the Accufix Multicenter Clinical Study and Worldwide Registry. , 1999, Circulation.

[12]  Safety alerts involving device therapy for arrhythmias. , 2001, JAMA.

[13]  C. Israel,et al.  Pacemaker systems as implantable cardiac rhythm monitors. , 2001, The American journal of cardiology.

[14]  W. Stevenson,et al.  Recalls and safety alerts involving pacemakers and implantable cardioverter-defibrillator generators. , 2001, JAMA.

[15]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.